Novaliq GmbH: Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol

HEIDELBERG, Germany, and CAMBRIDGE, MA, Aug. 9, 2022 /PRNewswire/ -- Novaliq, a biopharmaceutical company focusing on first- and best-in-class ocular therapeutics based on the unique EyeSol

Related Keywords

Cambridge ,Cambridgeshire ,United Kingdom ,Heidelberg ,Baden Wüberg ,Germany ,United States ,Netherlands ,Holland ,Americans ,Christian Roesky ,Mathias Hothum ,Novaliq Gmb ,Kostenloser Wertpapierhandel ,Prnewswire Novaliq ,Simone Angstmann Mehr ,Clin Ophthalmol ,Gmbh Co ,Drug Administration ,Novaliq Inc ,Cornea Clinical Committee ,Health Sciences ,New Drug Application ,Hopp Biotech ,Dry Eye ,Eye Products Market Report ,Clinical Committee ,Cataract Refract ,Dry Eye Disease ,Randomized Phase ,Clinical Phase ,Assess Efficacy ,Waterfree Cyclosporine Formulation ,Media Contact ,Novaliq ,Mbh ,Ubmits ,Drug ,Application ,Seeking ,Approval ,First ,Wind ,Disease ,Treatment ,Yclasol ,